Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction
Citations Over TimeTop 10% of 2016 papers
Abstract
The receptor for advanced glycation endproducts (RAGE) binds diverse ligands linked to chronic inflammation and disease. NMR spectroscopy and x-ray crystallization studies of the extracellular domains of RAGE indicate that RAGE ligands bind by distinct charge- and hydrophobicity-dependent mechanisms. The cytoplasmic tail (ct) of RAGE is essential for RAGE ligand-mediated signal transduction and consequent modulation of gene expression and cellular properties. RAGE signaling requires interaction of ctRAGE with the intracellular effector, mammalian diaphanous 1 or DIAPH1. We screened a library of 58,000 small molecules and identified 13 small molecule competitive inhibitors of ctRAGE interaction with DIAPH1. These compounds, which exhibit in vitro and in vivo inhibition of RAGE-dependent molecular processes, present attractive molecular scaffolds for the development of therapeutics against RAGE-mediated diseases, such as those linked to diabetic complications, Alzheimer's disease, and chronic inflammation, and provide support for the feasibility of inhibition of protein-protein interaction (PPI).
Related Papers
- → Advanced Glycation End Product Recognition by the Receptor for AGEs(2011)212 cited
- → The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines(2014)116 cited
- [AGEs and RAGE - advanced glycation end-products and their receptor in questions and answers].(2014)
- → ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTORS IN CARDIOVASCULAR DISEASES(2019)4 cited
- → Abstract 13855: The Impact of Plasma Levels of Receptor for Advanced Glycation End-products and High Mobility Group Box 1 in Patients With Pulmonary Hypertension(2014)